MENU
Monday, April 19th, 11:15AM EDT

ASH Anticoagulation Guidelines in Patients with COVID-19: A moving target

Sponsored by: Diagnostica Stago, Inc.
C.E. Credits: P.A.C.E. CE Florida CE
Speaker

Abstract
ASH Anticoagulation Guidelines in Patients with COVID-19: A moving target
 

The American Society of Hematology (ASH) published in February 2021 “Anticoagulation Guidelines in Patients with COVID-19”. (https://ashpublications.org/bloodadvances/article/5/3/872/475154/American-Society-of-Hematology-2021-guidelines-on). Despite the extensive work and using evidence-based methodology their findings were as follows:

The panel agreed on 2 recommendations. The panel issued conditional recommendations in favor of prophylactic-intensity anticoagulation over intermediate-intensity or therapeutic-intensity anticoagulation for patients with COVID-19–related critical illness or acute illness who do not have confirmed or suspected VTE.

These recommendations were based on very low certainty in the evidence, underscoring the need for high-quality, randomized controlled trials comparing different intensities of anticoagulation. They will be updated using a living recommendation approach as new evidence becomes available.

However, ongoing interim analysis of three randomized controlled trials, REMAP-CAP, ACTIV-4, and ATTACC (ClinicalTrials.gov: NCT 02735707, 04505774, and 04372589, respectively) will be used to update this recommendation.

 
Learning Objectives
  • Summarize the recent American Society of Hematology (ASH) guideline
  • Update the ongoing data based changes in recommendations based on ACTIV studies
  • Discuss relevance to coagulation laboratory based testing practices and clinical relevance
  • Offer some clinical perspectives from managing hemostatic dysfunction in COVID-19 and using laboratory testing for optimal management
 
 
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.  CE credits are available for this webinar up to 2 years from the date of the live broadcast

Show Resources
You May Also Like
NOV 30, 2021 10:00 AM PST
C.E. CREDITS
NOV 30, 2021 10:00 AM PST
Date: November 30, 2021 Time: 10:00am (PDT), 1:00pm (EDT) The prevalence of thyroid disease worldwide has served as a catalyst for healthcare providers to study various tools and methods to...
JAN 13, 2022 9:00 AM PST
C.E. CREDITS
JAN 13, 2022 9:00 AM PST
Date: January 13, 2022 Time: 09:00am (PST), 12:00pm (EST) Recently, the Infectious Disease Society of America released guidance on how to approach treatment of infections caused by multidrug...
MAR 16, 2022 8:00 AM PDT
C.E. CREDITS
MAR 16, 2022 8:00 AM PDT
Date: March 16, 2022 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CET) Handling of potent and/or hazardous substances is commonplace in sev.....
APR 28, 2022 8:00 AM PDT
APR 28, 2022 8:00 AM PDT
Date: April 28, 2022 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CEST) Human pluripotent stem cells (PSCs) and their derivatives hold great potentials in...
DEC 01, 2021 7:00 AM PST
C.E. CREDITS
DEC 01, 2021 7:00 AM PST
Date: December 01, 2021 Time: 7:00am (PST), 10:00am (EST) In the era of immuno-oncology, there is a growing need for the identification of new biomarkers predictive for sensitivity to anti-P...
FEB 24, 2022 10:00 AM PST
C.E. CREDITS
FEB 24, 2022 10:00 AM PST
Date: February 24, 2021 Time: 10:00am (PST), 1:00pm (EST) One of the largest global public health crises is the rise of antimicrobial-resistant infections. Globally, over 700,000 people die...
Loading Comments...
Show Resources
E